At a glance
ClinicalIndex Comparison Record- ✓Age 18-80 years
- ✓Acute ischemic stroke with NIHSS 7-20
- ✓Upper limb and lower limb weakness score ≥2 points
- ✓Onset within 48 hours
- ✕Intracranial hemorrhage on imaging
- ✕Severe consciousness impairment (NIHSS 1a >1)
- ✕Transient ischemic attack
- ✕Uncontrolled hypertension ≥220/120 mmHg
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06517173Phase 3RecruitingUpdate OverdueUpdated 21mo ago · Completion was 18mo agoA Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Y-3 in Chinese Subjects with Acute Ischemic Stroke
In Brief
A Phase 3 clinical trial evaluating Y-3 for injection and Placebo control group for Acute Ischemic Stroke. Currently recruiting, targeting 998 participants across 1 site.
Signals
Detailed Summary
This trial aims to evaluate the effectiveness and safety of Y-3 for injection in the treatment of patients with acute ischemic stroke within 48 hours of onset
Study Details
Timeline
Interventions
Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.